BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Lobbying for BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Filing Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$290,000.00

What this organization spent lobbying with its own staff. Reported using B: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Bills named in this filing 7

HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 5371
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
S 2211
Special Diabetes Program Reauthorization Act of 2025
HR 5461
Special Diabetes Program Reauthorization Act of 2025
HR 5488
Special Diabetes Program for Indians Reauthorization Act of 2025
HR 5467
Healthy Technology Act of 2021

Lobbying activity 2

Budget/Appropriations

H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 - Continuing Appropriations and Extensions Act of 2026

Health Issues

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians H.R. 5467 - Patient Access to Autoimmune Treatments Act Issues pertaining to NIH research Issues pertaining to prior authorization Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to insulin affordability

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.